SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media shares are under pressure as traders connect the decline to Trumps reported record-low approval and approaching midterms, while also questioning the companys business fundamentals. Some see the selloff as a speculative buying opportunity, but bearish sentiment dominates.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is drawing attention amid a sharp selloff and mounting concern over its heavy debt, costly financing, and ability to fund AI infrastructure expansion. Bears see refinancing and dilution risks outweighing its AI demand and backlog, while bulls point to those growth prospects and dip buying; a bullish analyst call and ARK purchases have not quelled the debate.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras steep post-IPO selloff is the dominant topic, with traders pointing to lockup-related share supply, reported insider selling and a TD Cowen price-target cut, alongside concerns about valuation and the companys ability to scale. Sentiment is largely bearish, though some investors view the decline as oversold and are adding to positions.

CleanSpark, Inc. is a bitcoin mining technology company, which engages in the management of data centers. Its operations include College Park, Norcross, Washington, Sandersville, Dalton, and Massena. The company was founded by S. Matthew Schultz and Bryan Huber on October 15, 1987 and is headquartered in Henderson, NV.

Cleanspark Inc

CleanSparks steep selloff alongside other bitcoin miners is driving discussion, with traders pointing to financing and debt costs, higher rates, and weak sector sentiment. Bulls argue the Meta-backed AI data-center lease and bitcoin holdings offer longer-term support, while skeptics say those positives have not offset near-term risks or the stocks underperformance.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

Anktivas FDA label expansion into papillary-only bladder cancer is the main catalyst, but IBRX has sold off despite the approval and positive trial updates. Bulls characterize the decline as a sell-the-news move or short pressure, while skeptics point to valuation, competition, and the need for revenue growth to support the companys expectations.

Uber Technologies, Inc. is a technology platform, which engages in the development and operation of technology applications, networks, and product to power movement from point A to point B. The firm offers ride services and merchants delivery service providers for meal preparation, grocery, and other delivery services. It operates through the following segments: Mobility, Delivery, and Freight. The Mobility segment refers to products that connect consumers with mobility drivers who provide rides in a variety of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, and taxis. The Delivery segment offers consumers the chance to search for and discover local restaurants, order a meal, and either pick-up at the restaurant or have the meal delivered. The Freight segment focuses on connecting carriers with shippers on its platform, and gives carriers upfront, transparent pricing, and the ability to book a shipment. The company was founded by Oscar Salazar Gaitan, Travis Kalanick, and Garrett Camp in 2009 and is headquartered in San Francisco, CA.

Uber Technologies Inc

Ubers prolonged share-price weakness is driving debate over whether robotaxi competition from Waymo and Tesla threatens its rides business, or whether that risk is overstated given its scale and cash generation. Some traders view the shares as undervalued and welcome the ezCater deal as a boost to delivery, while others remain frustrated by the stocks persistent underperformance.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivians prolonged slide to fresh 52-week lows is driving discussion, with traders focused on concerns about cash burn, execution and the R2 production ramp ahead of Q3 earnings, despite stronger deliveries. Some are buying the dip and pointing to R2 progress and VW backing, while others question profitability and whether upcoming results can change sentiment.

NuScale Power Corp. provides proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. Its products include VOYGR SMR Plants and Energy Exploration (E2) Centers. The company was founded by José N. Reyes in 2007 and is headquartered in Corvallis, OR.

NuScale Power Corporation - Ordinary Shares - Class A

NuScale Power Corp

NuScale shares are under pressure after UBS downgraded the stock, citing long commercialization timelines and a lack of firm customer commitments. Traders debate whether the selloff is an overreaction or reflects real execution and cash-burn risks, with some expecting a rebound and others questioning whether NuScale can secure projects and deliver reactors.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

Attention centers on the anticipated completion of Compass Pathways rolling FDA application for COMP360, its investigational psilocybin treatment for treatment-resistant depression, and the potential path toward approval and commercialization. Many traders see the regulatory milestone as a catalyst, while others are frustrated by the share-price weakness and uncertainty over the submission timeline and eventual FDA decision.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

EyePoints failed Phase 3 wet-AMD readout has intensified scrutiny of TKI-based treatments and weighed on OCUL, despite arguments that the setback removes a competitor. Traders disagree on whether the results cast doubt on AXPAXLIs prospects or are not comparable because OCUL uses a different molecule and has positive SOL-1 data; attention also centers on its pending NDA and the confirmatory SOL-R study.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Actinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial Officer

Actinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial Officer Actinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial OfficerPR NewswireNEW YORK, Oct. 15, 2026NEW YORK, Oct. 15, 2026...

What Makes Ovid Therapeutics (OVID) a Strong Momentum Stock: Buy Now?

Does Ovid Therapeutics (OVID) have what it takes to be a top stock pick for momentum investors? Let's find out.

Ovid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue Estimates

Ovid Therapeutics (OVID) delivered earnings and revenue surprises of +20.00% and +388.67%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Outlook Therapeutics, Inc. (OTLK) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Outlook Therapeutics, Inc. (OTLK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Lags Revenue Estimates

Lexicon (LXRX) delivered earnings and revenue surprises of 0.00% and -88.73%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Ovid Therapeutics (OVID) Q2 Earnings Expected to Decline

Ovid Therapeutics (OVID) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ovid Therapeutics (OVID) Appoints Kevin Norrett as Chief Business Officer

Ovid Therapeutics (OVID) Appoints Kevin Norrett as Chief Business Officer...

Ovid Therapeutics (OVID) to Release Earnings on Tuesday

Ovid Therapeutics (NASDAQ:OVID) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 12. (View Earnings Report at...

Ovid Therapeutics (NASDAQ:OVID) Sees Large Decline in Short Interest

Ovid Therapeutics (NASDAQ:OVID - Get Free Report) saw a significant decline in short interest during the month of April. As of April 15th, there was short interest totaling 6,957,013 shares, a decline of 25.5% from the March 31st total of 9,337,824 shares. Based on an average trading volume of...

Ovid Therapeutics (NASDAQ:OVID) Given Average Recommendation of "Buy" by Analysts

Shares of Ovid Therapeutics (NASDAQ:OVID - Get Free Report) have been assigned an average rating of "Buy" from the ten research firms that are covering the firm, MarketBeat.com reports. One research...

Ovid Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering better, gentler medicines for the brain. It discovers and develops differentiated, small molecule medicines for neurological and neuropsychiatric disorders with significant unmet need. The company was founded by Matthew During and Jeremy M. Levin on April 1, 2014 and is headquartered in New York, NY.

Ovid Therapeutics Inc

Ovid Therapeutics Stock Rallied 18% Pre-Market – Here’s Why

Equity

Bearish Sentiment

Shares of Ovid Therapeutics Inc. (OVID) jumped 18% in the pre-market session on Friday after the company announced positive results from an early-stage trial of its OV329, as well as the pricing of a $175 million placement.OV329 is being developed for the potential treatment of rare and treatment-resistant forms of epilepsy and seizures. It is believed to work by reducing the activity of GABA-AT, an enzyme that degrades GABA, an important inhibitory neurotransmitter in the brain. An increase in levels of GABA in the brain can potentially suppress neuronal hyperexcitability, known to cause seizures, the company said.The early-stage <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.ovidrx.com/news/news-details/2025/Ovid-announces-positive-topline-results-for-the-next-generation-GABA-aminotransferase-inhibitor-OV329-that-demonstrate-strong-inhibitory-activity-and-a-potential-best-in-category-safety-profile/default.aspx">study</a>, which enrolled 68 healthy volunteers, was aimed at evaluating the safety, tolerability, pharmacokinetic, and pharmacodynamic activity of OV329. The drug demonstrated statistically significant inhibition of GABA-AT, matching or exceeding the inhibition demonstrated by therapeutic doses of first-generation GABA-AT inhibitor Vigabatrin (VGB), the company said. The drug also demonstrated a favorable safety and tolerability profile, it added. &nbsp;The company is now looking forward to initiating a mid-stage study evaluating OV329 in adult patients with drug-resistant focal onset seizures. The study is expected to start in Q2 2026 and be completed in mid-2027.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/OVID">OVID stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:576/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_03_at_8_04_20_AM_png_cfbcdadc7f.webp" alt="OVID's Sentiment Meter and Message Volume as of 8:04 a.m. ET on Oct. 03, 2025 | Source: Stocktwits" width="576" height="60"><figcaption>OVID's Sentiment Meter and Message Volume as of 8:04 a.m. ET on Oct. 03, 2025 | Source: Stocktwits</figcaption></figure>Separately, Ovid on Friday also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.ovidrx.com/news/news-details/2025/Ovid-Therapeutics-Announces-Pricing-of-Private-Placement-Totaling-up-to-175-Million-in-Gross-Proceeds/default.aspx">announced</a> the pricing of a private placement totaling up to $175 million in proceeds. The financing transaction included participation from new investors alongside existing ones, the company said.The company stated that it intends to utilize the net proceeds from the initial closing of the financing deal, in conjunction with its existing cash, cash equivalents, and marketable securities, to fund research and development, general corporate expenses, and working capital requirements. It added that it expects its cash to fund its operating plan into 2028.A Stocktwits user applauded the funding news as “huge.”<stembedurl>https://stocktwits.com/Skeetz99/message/630905995</stembedurl>OVID stock is up 76% this year and approximately 45% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/esperion-shares-rally-after-patent-litigation-settlement-for-cholestrol-drugs/chCujWhR3Qb">Esperion Shares Rally After Patent Litigation Settlement For Cholesterol Drugs</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

The company is now looking forward to initiating a mid-stage study evaluating OV329 in adult patients with drug-resistant focal onset seizures.

EA Series Trust - EA Bridgeway Omni Small-Cap Value ETF

Vanguard Extended Market ETF

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Stocktwits

SpaceX

Netflix Inc

Meta Platforms Inc

Which earnings release are you most looking forward to this week: 

Stocktwits Polls

$OVID it showed red gravestone candle so that’s why it’s going down in after hours and 2.20 is major support . I will buy at support

Michael Hughes

$OVID might put 20k in here and come by next year . Bought this at .33 cents and made 30k and it’s proven to be very resilient to the over all market

$OVID institutions own almost 81% of this. And climbing. Pretty safe hold in a turbulent market

Feed

News

Sentiment

Earnings

Fundamentals

Info

OVID Ovid Therapeutics Inc

Fundamentals

Latest OVID News